Chronic angiotensin II receptor blockade induces cardioprotection during ischemia by increased PKC-ε expression in the mouse heart

Journal of Cardiovascular Pharmacology

Volumn 49, Issue 1, 2007, Pages 46-55

  Lange, Stefan A ^a   Wolf, Benita ^a   Schober, Kristin ^a   Wunderlich, Carsten ^a   Marquetant, Rainer ^a   Weinbrenner, Christof ^a   Strasser, Ruth H ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Angiotensin; Angiotensin converting enzyme inhibitors; Infarction; Preconditioning; Protein kinase C

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; CHELERYTHRINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ISOENZYME; PROPIDIUM IODIDE; PROTEIN KINASE C; PROTEIN KINASE C EPSILON; RAMIPRIL;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY OCCLUSION; ARTICLE; C57BL MOUSE; CONTROL GROUP; CONTROLLED STUDY; CYTOSOLIC FRACTION; DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; ENZYME ANALYSIS; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE REPERFUSION; HEART PROTECTION; IMMUNOBLOTTING; ISCHEMIC PRECONDITIONING; ISOLATED HEART; LONG TERM CARE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; UPREGULATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; HEART; MALE; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIUM; PROTEIN KINASE C-EPSILON; RAMIPRIL; RECEPTORS, ANGIOTENSIN; TETRAZOLES; TIME FACTORS;

EID: 33846596677     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31802c2f77     Document Type: Article

References (49)

1. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986; 74:1124-1136.
2. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev. 2003;83:1113-1151.
3. Yellon DM, Baxter GF, Garcia-Dorado D, et al. Ischaemic preconditioning: present position and future directions. Cardiovasc Res. 1998;37:21-33.
4. Leesar MA, Stoddard M, Ahmed M, et al. Preconditioning of human myocardium with adenosine during coronary angioplasty. Circulation. 1997;95:2500-2507.
5. Fryer RM, Auchampach JA, Gross GJ. Therapeutic receptor targets of ischemic preconditioning. Cardiovasc Res. 2002;55:520-525.
6. Leesar MA, Stoddard MF, Manchikalapudi S, et al. Bradykinin-induced preconditioning in patients undergoing coronary angioplasty. J Am Coll Cardiol. 1999;34:639-650.
7. Schultz JE, Rose E, Yao Z, et al. Evidence for involvement of opioid receptors in ischemic preconditioning in rat hearts. Am J Physiol. 1995;268:H2157-H2161.
8. Mackay K, Mochly-Rosen D. Localization, anchoring, and functions of protein kinase C isozymes in the heart. J Mol Cell Cardiol. 2001;33:1301-1307.
9. Weinbrenner C. Protein kinase C - the key-enzyme in ischemic preconditioning? In Downey JM, ed. Adenosine, cardioprotection and its clinical application. Norwell, MA: Kluwer Academic Publishers; 1997;73-91
10. Ytrehus K, Liu Y, Downey JM. Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am J Physiol. 1994;266:H1145-H1152.
11. Baines CP, Song CX, Zheng YT, et al. Protein kinase Cepsilon interacts with and inhibits the permeability transition pore in cardiac mitochondria. Circ Res. 2003;92:873-880.
12. Liu GS, Cohen MV, Mochly-Rosen D, et al. Protein kinase C-epsilon is responsible for the protection of preconditioning in rabbit cardiomyocytes. J Mol Cell Cardiol. 1999;31:1937-1948.
13. Ping P, Zhang J, Qiu Y, et al. Ischemic preconditioning induces selective translocation of protein kinase C isoforms epsilon and eta in the heart of conscious rabbits without subcellular redistribution of total protein kinase C activity. Circ Res. 1997;81:404-414.
14. Jalowy A, Schulz R, Heusch G. AT1 receptor blockade in experimental myocardial ischemia/reperfusion. Basic Res Cardiol. 1998;93:85-91.
15. Schwarz ER, Montino H, Fleischhauer J, et al. Angiotensin II receptor antagonist EXP 3174 reduces infarct size comparable with enalaprilat and augments preconditioning in the pig heart. Cardiovasc Drugs Ther. 1997;11:687-695.
16. Weidenbach R, Schulz R, Gres P, et al. Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT(1)-receptor antagonism. Br J Pharmacol. 2000;131:138-144.
17. Liu Y, Tsuchida A, Cohen MV, et al. Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts. J Mol Cell Cardiol. 1995;27:883-892.
18. Ford WR, Clanachan AS, Jugdutt BI. Opposite effects of angiotensin AT1 and AT2 receptor antagonists on recovery of mechanical function after ischemia-reperfusion in isolated working rat hearts. Circulation. 1996;94:3087-3089.
19. Diaz RJ, Wilson GJ. Selective blockade of AT1 angiotensin II receptors abolishes ischemic preconditioning in isolated rabbit hearts. J Mol Cell Cardiol. 1997;29:129-139.
20. Kloner RA, Shook T, Przyklenk K, et al. Previous angina alters in-hospital outcome in TIMI 4. A clinical correlate to preconditioning? Circulation. 1995;91:37-45.
21. Yang XP, Liu YH, Mehta D, et al. Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B(2) kinin receptor gene knockout mice. Circ Res. 2001;88:1072-1079.
22. Furukawa Y, Matsumori A, Hirozane T, et al. Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model. A comparative study with captopril. Circulation. 1996;93:333-339.
23. Yang T, Huang YG, Ye W, et al. Influence of genetic background and gender on hypertension and renal failure in COX-2-deficient mice. Am J Physiol Renal Physiol. 2005;288:F1125-F1132.
24. Wolff RA, Chien GL, Van Winkle DM. Propidium iodide compares favorably with histology and triphenyl tetrazolium chloride in the assessment of experimentally-induced infarct size. J Mol Cell Cardiol. 2000;32:225-232.
25. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
26. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685.
27. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979;76:4350-4354.
28. Tanaka A, Matsumori A, Wang W, et al. An angiotensin II receptor antagonist reduces myocardial damage in an animal model of myocarditis. Circulation. 1994;90:2051-2055.
29. Falck G. Hyperosmotic pretreatment reduces infarct size in the rat heart. Physiol Res. 1999;48:331-340.
30. Noguchi T, Chen Z, Bell SP, et al. Activation of PKC decreases myocardial O2 consumption and increases contractile efficiency in rats. Am J Physiol Heart Circ Physiol. 2001;281:H2191-H2197.
31. Jalowy A, Schulz R, Dorge H, et al. Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs. J Am Coll Cardiol. 1998;32:1787-1796.
32. Kumar D, Menon V, Ford WR, et al. Effect of angiotensin II type 2 receptor blockade on activation of mitogen-activated protein kinases after ischemia-reperfusion in isolated working rat hearts. J Cardiovasc Pharmacol Ther. 2003;8:285-296.
33. Xu Y, Menon V, Jugdutt BI. Cardioprotection after angiotensin II type 1 blockade involves angiotensin II type 2 receptor expression and activation of protein kinase C-epsilon in acutely reperfused myocardial infarction in the dog. Effect of UP269-6 and losartan on AT1 and AT2-receptor expression and IP3 receptor and PKCepsilon proteins. J Renin Angiotensin Aldosterone Syst. 2000;1:184-195.
34. Gray MO, Karliner JS, Mochly-Rosen D. A selective epsilon-protein kinase C antagonist inhibits protection of cardiac myocytes from hypoxia-induced cell death. J Biol Chem. 1997;272:30945-30951.
35. Kawamura S, Yoshida K, Miura T, et al. Ischemic preconditioning translocates PKC-delta and -epsilon, which mediate functional protection in isolated rat heart. Am J Physiol. 1998;275:H2266-H2271.
36. Inagaki K, Hahn HS, Dorn GW, et al. Additive protection of the ischemic heart ex vivo by combined treatment with delta-protein kinase C inhibitor and epsilon-protein kinase C activator. Circulation. 2003;108:869-875.
37. Hassouna A, Matata BM, Galinanes M. PKC-epsilon is upstream and PKC-alpha is downstream of mitoKATP channels in the signal transduction pathway of ischemic preconditioning of human myocardium. Am J Physiol Cell Physiol. 2004;287:C1418-C1425.
38. Chou MM, Hou W, Johnson J, et al. Regulation of protein kinase C zeta by PI 3-kinase and PDK-1. Curr Biol. 1998;8:1069-1077.
39. Bartunek J, Weinberg EO, Tajima M, et al. Angiotensin II type 2 receptor blockade amplifies the early signals of cardiac growth response to angiotensin II in hypertrophied hearts. Circulation. 1999;99:22-25.
40. Xu Y, Clanachan AS, Jugdutt BI. Enhanced expression of angiotensin II type 2 receptor, inositol 1,4, 5-trisphosphate receptor, and protein kinase cepsilon during cardioprotection induced by angiotensin II type 2 receptor blockade. Hypertension. 2000;36:506-510.
41. Jugdutt BI, Xu Y, Balghith M, et al. Cardioprotection induced by AT1R blockade after reperfused myocardial infarction: association with regional increase in AT2R, IP3R and PKCepsilon proteins and cGMP. J Cardiovasc Pharmacol Ther. 2000;5:301-311.
42. Nozawa Y, Miura T, Tsuchida A, et al. Chronic treatment with an ACE inhibitor, temocapril, lowers the threshold for the infarct size-limiting effect of ischemic preconditioning. Cardiovasc Drugs Ther. 1999;13:151-157.
43. Morris SD, Yellon DM. Angiotensin-converting enzyme inhibitors potentiate preconditioning through bradykinin B2 receptor activation in human heart. J Am Coll Cardiol. 1997;29:1599-1606.
44. Hartman JC, Wall TM, Hullinger TG, et al. Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol. 1993;21:996-1003.
45. Goto M, Liu Y, Yang XM, et al. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res. 1995;77:611-621.
46. Sato M, Engelman RM, Otani H, et al. Myocardial protection by preconditioning of heart with losartan, an angiotensin II type 1-receptor blocker: implication of bradykinin-dependent and bradykinin-independent mechanisms. Circulation. 2007;:III346-III351.
47. Linz W, Wiemer G, Gohlke P, et al. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 1995;47:25-49.
48. Simonis G, Braun MU, Kirrstetter M, et al. Mechanisms of myocardial remodeling: ramiprilat blocks the expressional upregulation of protein kinase C-epsilon in the surviving myocardium early after infarction. J Cardiovasc Pharmacol. 2003;41:780-787.
49. Kim L, Lee T, Fu J, et al. Characterization of MAP kinase and PKC isoform and effect of ACE inhibition in hypertrophy in vivo. Am J Physiol. 1999;277:H1808-H1816.